Autopsy report · NCT02333955

A Phase 2 Extension of Study GCS-100-CS-4003

“Corporate decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

La Jolla Pharmaceutical Company

Sponsor type

Industry

Conditions

Chronic Kidney Disease

Interventions

GCS-100

Participants

0

Sites

5

Countries

United States

Trials that died the same way

• Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
  “Company decision” (90% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (88% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (86% match in meaning)
• Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy
  “Business decision” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.